Jarrod Tremayne, Ph.D. - Publications

2009 University of Nebraska Medical Center, Omaha, NE, United States 
Immunology, Pathology

12/17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Mehla K, Tremayne J, Grunkemeyer JA, O'Connell KA, Steele MM, Caffrey TC, Zhu X, Yu F, Singh PK, Schultes BC, Madiyalakan R, Nicodemus CF, Hollingsworth MA. Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors. Cancer Immunology, Immunotherapy : Cii. PMID 29204701 DOI: 10.1007/S00262-017-2095-7  0.48
2015 Storm EE, Durinck S, de Sousa E Melo F, Tremayne J, Kljavin N, Tan C, Ye X, Chiu C, Pham T, Hongo JA, Bainbridge T, Firestein R, Blackwood E, Metcalfe C, Stawiski EW, et al. Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function. Nature. PMID 26700806 DOI: 10.1038/Nature16466  0.48
2015 Yin Y, Djakovic S, Marsters S, Tien J, Peng J, Tremayne J, Lee G, Neve RM, Wu Y, Merchant M, Ashkenazi A, Carter PJ. Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Anti-tumor Activity. Molecular Cancer Therapeutics. PMID 26269606 DOI: 10.1158/1535-7163.Mct-14-1050  0.48
2015 Asundi J, Crocker L, Tremayne J, Chang P, Sakanaka C, Tanguay J, Spencer S, Chalasani S, Luis E, Gascoigne K, Desai R, Raja R, Friedman BA, Haverty PM, Polakis P, et al. An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3252-62. PMID 25862760 DOI: 10.1158/1078-0432.Ccr-15-0156  0.48
2015 Leong SR, Liang WC, Wu Y, Crocker L, Cheng E, Sampath D, Ohri R, Raab H, Hass PE, Pham T, Firestein R, Li D, Schutten M, Stagg NJ, Ogasawara A, ... ... Tremayne J, et al. An anti-b7-h4 antibody-drug conjugate for the treatment of breast cancer. Molecular Pharmaceutics. 12: 1717-29. PMID 25853436 DOI: 10.1021/Mp5007745  0.48
2014 Liu X, Yi C, Wen Y, Radhakrishnan P, Tremayne JR, Dao T, Johnson KR, Hollingsworth MA. Interactions between MUC1 and p120 catenin regulate dynamic features of cell adhesion, motility, and metastasis. Cancer Research. 74: 1609-20. PMID 24371222 DOI: 10.1158/0008-5472.Can-13-2444  0.48
2013 Xiao Y, Elkins K, Durieux JK, Lee L, Oeh J, Yang LX, Liang X, DelNagro C, Tremayne J, Kwong M, Liederer BM, Jackson PK, Belmont LD, Sampath D, O'Brien T. Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618. Neoplasia (New York, N.Y.). 15: 1151-60. PMID 24204194 DOI: 10.1593/Neo.131304  0.48
2013 Zheng X, Bair KW, Bauer P, Baumeister T, Bowman KK, Buckmelter AJ, Caligiuri M, Clodfelter KH, Feng Y, Han B, Ho YC, Kley N, Li H, Liang X, Liederer BM, ... ... Tremayne J, et al. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). Bioorganic & Medicinal Chemistry Letters. 23: 5488-97. PMID 24021463 DOI: 10.1016/J.Bmcl.2013.08.074  0.48
2013 Ong CC, Jubb AM, Jakubiak D, Zhou W, Rudolph J, Haverty PM, Kowanetz M, Yan Y, Tremayne J, Lisle R, Harris AL, Friedman LS, Belvin M, Middleton MR, Blackwood EM, et al. P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. Journal of the National Cancer Institute. 105: 606-7. PMID 23535073 DOI: 10.1093/Jnci/Djt054  0.48
2012 Vijapurkar U, Robillard L, Zhou S, Degtyarev M, Lin K, Truong T, Tremayne J, Ross LB, Pei Z, Friedman LS, Blackwood EM, Belvin M. mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations. Cancer Letters. 326: 168-75. PMID 22902509 DOI: 10.1016/j.canlet.2012.08.011  0.48
2011 Eggers JP, Grandgenett PM, Collisson EC, Lewallen ME, Tremayne J, Singh PK, Swanson BJ, Andersen JM, Caffrey TC, High RR, Ouellette M, Hollingsworth MA. Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6140-50. PMID 21825040 DOI: 10.1158/1078-0432.Ccr-10-2288  0.48
2007 Ashour AE, Turnquist HR, Burns N, Wang X, Lin X, Tremayne J, Hollingsworth MA, Blonder JM, Rosenthal GJ, Talmadge JE, Solheim JC. Flt3 ligand delivered in a pluronic formulation prolongs the survival of mice with orthotopic pancreatic adenocarcinoma. Cancer Biotherapy & Radiopharmaceuticals. 22: 235-8. PMID 17600470 DOI: 10.1089/Cbr.2007.336  0.48
Low-probability matches
2020 Daemen A, Cooper J, Myrta S, Wongchenko MJ, Lin E, Long JE, Foreman O, Modrusan Z, Tremayne JR, de la Cruz CC, Merchant M, Martin SE, Yan Y, Junttila MR. Transcriptional subtypes resolve tumor heterogeneity and identify vulnerabilities to MEK inhibition in lung adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33023953 DOI: 10.1158/1078-0432.CCR-20-1835  0.01
2014 Merchant M, Chan J, Orr C, Cheng J, Wang X, Hunsaker T, Wagle M, Huang S, Tremayne J, Ngu H, Solon M, Eastham-Anderson J, Koeppen H, Friedman L, Belvin M, et al. 387 Combination of the ERK inhibitor GDC-0994 with the MEK inhibitor cobimetinib significantly enhances anti-tumor activity in KRAS and BRAF mutant tumor models European Journal of Cancer. 50: 124. DOI: 10.1016/S0959-8049(14)70513-1  0.01
1998 Hayes PJ, Tremayne JF, Gibson RC. Induction heating for single shot melting processes Foundryman. 91: 23-28.  0.01
1984 Perks MC, Parish RB, Hayes PJ, Tremayne JF. LOOP-HEATED LADLE FOR HOLDING MOLTEN METAL 0.01
1983 Tremayne JF. IMPEDANCE AND PHASE BALANCING OF MAINS-FREQUENCY INDUCTION FURNACES Iee Proceedings B: Electric Power Applications. 130: 161-170.  0.01
Hide low-probability matches.